Cannabix Technologies to Beta Test Marijuana Breathalyzer with Occupational Health Clinic in Southern California
November 23, 2020
Vancouver, British Columbia, November 23, 2020 -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the “Company or Cannabix”) developer of the Cannabix Marijuana Breathalyzer for law enforcement and the workplace, is pleased to report that it plans to begin beta testing its version 3.0 THC Breath Analyzer (“THCBA”) in southern California with an occupational health care provider located in Newport Beach. Cannabix expects to deliver its latest version of the THCBA to Alipour Medical Centre early in the new year. Alipour Medical Centre provides drug and alcohol testing services to a number of local employers in the state. The THCBA is an ideal device for employers and other markets who are seeking a way to quickly, easily and non-invasively test for recent use of ∆9-tetrahydrocannabinol (“THC”) - the psychoactive component of marijuana that causes impairment. Cannabix will be seeking additional organizations for beta testing and welcomes interested parties to contact us via our website.
Employers everywhere are struggling with the limitations of current drug testing technology in identifying recent use of marijuana that may be causing impairment during work hours and differentiating this from recreational and medical use during nonwork hours/days.
The Cannabix device allows for more relevant THC detection from breath allowing employers to create an onsite regiment whereby they can perform pre-access testing for recent use of marijuana before and during work hours, instead of testing for drug use when employees are not at work. Cannabix will be beta testing its device in order to continue training the device’s machine learning database and improve user experience through testing feedback. The THCBA has been built to provide easy to understand screen prompts for the positive and negative detection of THC in breath in a portable manner, and can be administered without extensive training.
Current forms of testing for marijuana use can identify THC ranging from minutes to days prior to actual use, making it impossible to show the difference between the two. Studies¹ have shown that breath is a better indicator of impairment than saliva, blood, or urine because THC is present in breath for a relatively short period of time (1-3 hours); whereas, it is excreted at detectable levels in other body fluids for many hours, days, or even weeks after smoking. This short time period of detection in breath aligns with the peak impairment window.
Dr. Nima Alipour, CEO of Alipour Medical Corp, stated, “We are very pleased to be using one of the world’s first marijuana breathalyzers in our medical facility. We know first-hand how the legalization of marijuana has affected employers in our state. As occupational health practitioners based in Orange County, we understand the challenges that employers are facing in providing relevant drug testing for existing and new employees. We advise corporations on how best to keep their workforce safe; identifying safety issues as they pertain to impairment, while taking into account employee rights in an environment of state legalization. Alipour Medical prides itself on deploying cutting edge technology in our practice and we look forward to helping with research, and ultimately beta testing devices alongside Cannabix Technologies in California.”
The information in these press releases is historical in nature, has not been updated, and is current only to the date indicated in the particular press release. This information may no longer be accurate and therefore you should not rely on the information contained in these press releases. To the extent permitted by law, Cannabix Technologies Inc. and its employees, agents and consultants exclude all liability for any loss or damage arising from the use of, or reliance on, any such information, whether or not caused by any negligent act or omission.